Related Experiment Video

Updated: Dec 9, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.0K

Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3

Mathilde Boulpicante1, Romain Darrigrand1, Alison Pierson1

  • 1Immunologie des Tumeurs et Immunothérapie, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.

Oncoimmunology
|September 14, 2020
PubMed

Insights

Cancer cells evade immune surveillance by increasing PSME3 proteasome activator, which destroys tumor-specific peptides. Targeting PSME3 could enhance cancer immunotherapy effectiveness.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • CD8+ T cell-based cancer immunotherapy highlights the need to understand MHC-I peptide ligand generation and tumor immune escape mechanisms.
  • Pioneer translation products (PTPs) from nuclear mRNA translation are a source of tumor-specific peptides, linked to oncogenesis-associated aberrant splicing and transcription.

Purpose of the Study:

  • To investigate the role of PSME3 proteasome activator in cancer cell immune evasion.
  • To determine if PSME3 impacts the processing of PTP-derived peptides in the nucleus.
  • To explore PSME3 as a potential therapeutic target for cancer immunotherapy.

Main Methods:

  • Analysis of PSME3 proteasome activator expression in cancer cells.
  • Assessment of PTP-derived peptide levels in the nucleus.
  • Evaluation of cancer cell susceptibility to immunosurveillance.

Main Results:

  • Up-regulation of PSME3 proteasome activator in cancer cells leads to enhanced destruction of PTP-derived peptides within the nucleus.
  • Increased PSME3 activity facilitates cancer cell escape from immunosurveillance.
  • PSME3 plays a previously unrecognized role in antigen processing.

Conclusions:

  • PSME3 proteasome activator contributes to cancer immune evasion by degrading nuclear tumor-specific peptides.
  • Targeting PSME3 presents a novel strategy to improve the efficacy of cancer immunotherapy.
Keywords:
Tumor immune responsesactivator PSME3pioneer translation productsproteasome regulations

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.9K
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.4K
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.8K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.2K